Actively Recruiting
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Led by Peking University People's Hospital · Updated on 2025-04-16
1000
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
P
Peking University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are: * How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer? * Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival? * Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?
CONDITIONS
Official Title
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Non-small cell lung cancer with stage IA to IIIA (8th edition TNM classification) planning to undergo curative surgery or neoadjuvant therapy
- Solid nodules larger than 1 cm or ground-glass nodules larger than 1.5 cm on imaging
- No history of other malignancies except non-small cell lung cancer in the past 5 years
- Well-preserved specimens and accessible imaging documents
You will not qualify if you...
- Age under 18 years
- Non-small cell lung cancer with pathologic stage IIIB to IV (8th edition TNM classification)
- Pathology confirms diagnosis other than non-small cell lung cancer
- History of other malignancies except non-small cell lung cancer in the past 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
K
Kezhong Chen, MD
CONTACT
X
Xiaoqiu Yuan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here